Patient-Derived Cells: The Essential Foundation for Personalized Drug Development.
Key Takeaways:
• Most personalized rare disease treatments begin with patient-derived cells: living copies of your child's cells that carry their exact mutation.
• A simple skin biopsy or blood draw starts a process to create cells that can later become essential for treatment design and testing.
• COMBINEDBrain, founded by Dr. Terry Jo Bichell, banks cells for 65+ neurodevelopmental disease communities, reducing costs and accelerating research for participating families.
• Because cell line development takes time, it is important to start this process very early, often immediately after a genetic disease diagnosis, provided that it is reasonable to believe a personalized genetic therapy may be possible for the patient (for more on this, submit your case to Nome for a free evaluation).
In this article, we break down what patient-derived cells are, how they are made, what they cost, and why they are so important.
What Are Patient-Derived Cells?
Patient-derived cells are living cells grown from a sample of your child's tissue, usually from a small skin biopsy or a blood draw. These cells carry your child's complete genome, including the specific mutation that causes their disease. That is what makes them valuable: they are not generic lab cells. They are your child's cells, with your child's mutation, behaving the way your child's cells behave.
Researchers use these cells for several things: to understand what the mutation actually does at the cellular level, to test whether a potential therapy fixes the problem, to measure safety before the therapy is given to your child, and to generate the evidence the FDA requires for regulatory approval.
There are several types of patient-derived cells, ranging from simple (skin fibroblasts you can grow in a few weeks) to complex (brain organoids that take months to develop). Which type your child's program needs depends on what disease they have and which organ is affected.
The Cell Pipeline: From Skin Biopsy to Disease Model
Everything starts with a small tissue sample from your child. The most common approach is a skin punch biopsy, a 2 to 4 millimeter circle of skin taken under local anesthetic in an outpatient visit. It takes about 10 minutes and heals in about a week. Alternatively, researchers can work from a standard blood draw. Both approaches provide cells that carry your child's complete genetic information.
From that starting sample, the pipeline works in stages. Each stage builds on the last and produces a more sophisticated disease model. The total elapsed time from skin biopsy to research-ready disease model cells is typically 3 to 6 months, depending on which cell type is needed. Here is what each step costs and how long it takes:
Stage 1: Fibroblasts (Weeks 1-3, $1,000-$3,000). The skin cells from the biopsy are placed in a dish with growth medium. Over 2 to 3 weeks, cells called fibroblasts grow out from the tissue and multiply. These are your child's skin cells. They carry the mutation. They can be frozen and banked for years. Fibroblasts are the cheapest and fastest patient cells to obtain, and they are useful for initial gene expression testing, some drug screening, and as the starting material for the next step.
Stage 2: iPSCs (Weeks 4-14, $5,000-$20,000). This is the transformative step. Fibroblasts are "reprogrammed" into stem cells using a set of proteins (originally discovered by Shinya Yamanaka, who won the Nobel Prize for this work in 2012). The resulting cells, called iPSCs, are essentially returned to an embryonic-like state. They can become almost any cell type in the human body. This step alone takes 8 to 12 weeks and the cost depends on the lab, the number of clones generated, and the quality control performed. Cumulative elapsed time at this point: roughly 3 months.
Stage 3: Differentiated cells (Weeks 15-26+, $20,000-30,000+. often higher costs driven by more complex cell types). iPSCs are then guided, using specific growth factors and culture conditions, into the cell type affected by your child's disease. If the disease affects the brain, researchers differentiate iPSCs into neurons. If it affects the liver, into hepatocytes. If it affects the eyes, into retinal pigment epithelium cells (RPE). These differentiated cells now carry your child's mutation in the right tissue context. This is the disease model.
Stage 4: Organoids (add 4-24 weeks, $50,000-$100,000+, often higher costs driven by more complex cell types). The most advanced step, and not available nor needed for every therapy or tissue type. Organoids are three-dimensional, miniature organ-like structures grown from iPSCs. They are the closest thing to a real organ you can grow in a dish. Organoid technology is still developing for many types of tissues, and it is imperative to find a high quality academic group or lab partner to ensure quality.
Why they matter
Not every program needs every cell type. For many ASO programs, fibroblasts or basic iPSC-derived cells are sufficient to screen candidates and measure efficacy. For gene editing programs, iPSC-derived cells in the target tissue are typically needed. The key question to ask your research team early: do we need a 3D organoid, or will a 2D differentiated culture give us the data we need to move forward? The answer depends on the disease, the tissue, and what is actually possible today.
Why Patient Cells Are Critical to personalized medicine research
Patient-derived cells are required infrastructure for developing any individualized therapy. Without them, researchers cannot confirm that the mutation causes the expected cellular dysfunction, screen ASO candidates or gene editing guides, measure whether a therapy restores function, perform the safety testing (off-target analysis) required for gene editing, or generate the evidence the FDA requires for an IND filing.
In the Baby KJ case, patient-derived cells were central to every stage: the base editor was tested on cells carrying KJ's mutation, the off-target analysis was performed on KJ's genome, and the preclinical evidence package submitted to the FDA was built on patient cell data.
Skin Biopsy vs. Blood Draw: Which Starting Material Is Better?
Both work. A skin punch biopsy is the most common starting point because fibroblasts grow out of the tissue quickly and reliably, and the reprogramming efficiency from fibroblasts to iPSCs is high. The biopsy itself is small (2-4mm), uses local anesthetic, and heals within a week.
A standard blood draw is the alternative. Peripheral blood mononuclear cells (PBMCs) can be reprogrammed into iPSCs using the same technology. The success rate is slightly lower and the process can be less efficient, but it avoids a biopsy entirely. This is particularly useful for infants or children where a skin biopsy is difficult or for families who prefer to avoid any minor procedure.
For ASO programs specifically, fibroblasts from a skin biopsy are usually the first choice because they are the most reliable and efficient starting material. But for families where a biopsy is not practical, blood-derived iPSCs are a well-validated alternative. Either way, the resulting iPSCs are functionally equivalent.
COMBINEDBrain: How Disease Communities Are Pooling Cell Banking Resources
One of the most important developments in patient cell infrastructure is COMBINEDBrain, a nonprofit consortium founded by Dr. Terry Jo Bichell, a neuroscientist and the mother of a son with Angelman syndrome. COMBINEDBrain represents more than 65 rare genetic neurodevelopmental disorder advocacy groups and operates a centralized biorepository in partnership with IBX.
The model is straightforward: families donate blood samples or skin biopsies at coordinated collection events. COMBINEDBrain's lab partner isolates fibroblasts and PBMCs, generates iPSC lines, and banks everything in a centralized, HIPAA-compliant repository. Those samples are then made available to researchers and industry at the lowest possible cost, with de-identified health histories attached so that biological data can be properly interpreted.
Foundations like the CACNA1A Foundation have invested in iPSC lines through COMBINEDBrain and now have 8 completed patient-derived iPSC lines available for researchers (CACNA1A Foundation, cacna1a.org, August 2024). Many other patient organizations have done similar work to ensure they have proper starting materials for foundational research.
This model is replicable for any rare disease community. If your foundation or patient group does not yet have banked cell lines, COMBINEDBrain offers the infrastructure to start.
What Should You Do Right Now?
If your child has a confirmed genetic diagnosis and you are exploring treatment options, the single most valuable thing you can do immediately is establish if there is a reasonable chance that a personalized genetic therapy could be possible. If there is a reasonable chance, for many patients, parents, foundations, and researchers, it is worth the investment to begin cell line development immediately. This is a scientific and financial decision that should not be made lightly and should be done in consultation of experts (see disclosures below - this blog is not medical advice). With this in mind, the information shared here should provide a compelling view on why this step may be a wise one.
Ask your clinician about arranging a skin biopsy. Many academic medical centers can process and bank the sample. If that option is not available, Nome can connect you with a qualified lab.
What Nome Does
Nome includes cell line strategy as part of every patient evaluation. When we assess your child's mutation, we determine which cell types the program will need, identify the right labs to generate them, estimate the cost and timeline, and coordinate the biopsy and banking process if it has not already been done. We work with partners including COMBINEDBrain's biorepository network to ensure samples are banked, tracked, and available for downstream therapeutic development.
For active programs, we manage the full cell line pipeline: from biopsy logistics to iPSC reprogramming to differentiation into the target tissue. We know which CROs deliver on time, which labs have the right expertise for each tissue type, and how to sequence the work so it does not become a bottleneck.
The first step is always the same: get a genetic diagnosis, then find out what is possible.
Submit your child's genetic diagnosis for a free evaluation at nome.bio.
REFERENCES
1. Takahashi K, Yamanaka S. Cell. 2006;126(4):663-676. (Discovery of iPSC reprogramming)
3. Wiley LA, et al. Curr Protoc Hum Genet. 2016. (cGMP-compliant iPSC from skin biopsy)
4. Ahrens-Nicklas R, Musunuru K, et al. NEJM. 2025. (Baby KJ, patient cell use in gene editing)
5. Evotec. "iPSC Drug Discovery Platform." evotec.com. (20+ differentiated cell types)
6. Lancaster MA, Knoblich JA. Science. 2014;345(6194):1247125. (Cerebral organoids)
8. CACNA1A Foundation. "Biobanking." cacna1a.org. August 2024. (8 iPSC lines, $50K+ invested)
10. Foundation for Prader-Willi Research. "Building the SYS Biorepository." fpwr.org, November 2025.
This article is for informational purposes only and does not constitute medical advice. Cost and timeline data is subject to change and is estimated only at time of publication.